Notice2021-13851
Advisory Council on Alzheimer's Research, Care, and Services; Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 29, 2021
Issuing agencies
Health and Human Services Department
Abstract
This notice announces the public meeting of the Advisory Council on Alzheimer's Research, Care, and Services (Advisory Council). The Advisory Council provides advice on how to prevent or reduce the burden of Alzheimer's disease and related dementias on people with the disease and their caregivers. During the July 19, 2021 meeting the Advisory Council will discuss the implications of and opportunities presented by the approval of aducanumab. The Council will also hear updates from federal workgroups on efforts undertaken in the last quarter. The risk reduction subcommittee will present a summary of their work and recommendations. The research, clinical care, and long- term services and supports subcommittees will present recommendations and the Council will vote on adopting them.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 122 (Tuesday, June 29, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 122 (Tuesday, June 29, 2021)]
[Notices]
[Pages 34242-34243]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-13851]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Council on Alzheimer's Research, Care, and Services;
Meeting
AGENCY: Assistant Secretary for Planning and Evaluation, HHS.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: This notice announces the public meeting of the Advisory
Council on Alzheimer's Research, Care, and Services (Advisory Council).
The Advisory Council provides advice on how to prevent or reduce the
burden of Alzheimer's disease and related dementias on people with the
disease and their caregivers. During the July 19, 2021 meeting the
Advisory Council will discuss the implications of and opportunities
presented by the approval of aducanumab. The Council will also hear
updates from federal workgroups on efforts undertaken in the last
quarter. The risk reduction subcommittee will present a summary of
their work and recommendations. The research, clinical care, and long-
term services and supports subcommittees will present recommendations
and the Council will vote on adopting them.
DATES: The meeting will be held on July 19, 2021 from 12:30 p.m. to
4:30 p.m. EST.
ADDRESSES: The meeting will be virtual, streaming live at <a href="http://www.hhs.gov/live">www.hhs.gov/live</a>.
Comments: Time is allocated on the agenda to hear public comments
from 4:00 p.m. to 4:30 p.m. The time for oral comments will be limited
to two (2) minutes per individual. In order to provide a public
comment, please register by emailing your name to <a href="/cdn-cgi/l/email-protection#432d223322032b2b306d242c35"><span class="__cf_email__" data-cfemail="412f203120012929326f262e37">[email protected]</span></a> by
Thursday, July 15. On Friday, July 16, registered commenters will
receive both a dial-in number and a link to join the meeting virtually;
individuals will have the choice to either join virtually via the link,
or to call in only by using the dial-in number. Note: There may be a
30-45 second delay in the livestream video presentation of the
conference. For this reason, if you have pre-registered to submit a
public comment, it is important to connect to the meeting by 3:45 p.m.
to ensure that you do not miss your name and allotted time when called.
If you miss your name and allotted time to speak, you may not be able
to make your public comment. All participant audio lines will be muted
for the duration of the meeting and only unmuted by the Host at the
time of the participant's public comment. Should you have questions
during the session email <a href="/cdn-cgi/l/email-protection#234d425342634b4b500d444c55"><span class="__cf_email__" data-cfemail="caa4abbaab8aa2a2b9e4ada5bc">[email protected]</span></a> and someone will respond to your
message as quickly as possible.
In order to ensure accuracy, please submit a written copy of oral
comments for the record by emailing <a href="/cdn-cgi/l/email-protection#b5dbd4c5d4f5ddddc69bd2dac3"><span class="__cf_email__" data-cfemail="d8b6b9a8b998b0b0abf6bfb7ae">[email protected]</span></a> by Tuesday, July 20.
These comments will be shared on the website and reflected in the
meeting minutes.
In lieu of oral comments, formal written comments may be submitted
for the record by Tuesday, July 20 to Helen Lamont, Ph.D., OASPE, 200
Independence Avenue SW, Room 424E, Washington, DC 20201. Comments may
also be sent to <a href="/cdn-cgi/l/email-protection#d0beb1a0b190b8b8a3feb7bfa6"><span class="__cf_email__" data-cfemail="8be5eafbeacbe3e3f8a5ece4fd">[email protected]</span></a>. Those submitting written comments should
identify themselves and any relevant organizational affiliations.
FOR FURTHER INFORMATION CONTACT: Helen Lamont, 202-260-6075,
<a href="/cdn-cgi/l/email-protection#48202d242d266624292527263c0820203b662f273e"><span class="__cf_email__" data-cfemail="5d353831383373313c303233291d35352e733a322b">[email protected]</span></a>. Note: The meeting will be available to the public
live at <a href="http://www.hhs.gov/live">www.hhs.gov/live</a>.
SUPPLEMENTARY INFORMATION: Notice of these meetings is given under the
Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and
(a)(2)). Topics of the Meeting: Aducanumab, dementia risk reduction,
recommendations.
Procedure and Agenda: The meeting will be webcast at <a href="http://www.hhs.gov/live">www.hhs.gov/live</a> and video recordings will be added to the National Alzheimer's
Project Act website when available, after the meeting.
Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National
Alzheimer's Project Act. The panel is governed by provisions of
Public
[[Page 34243]]
Law 92-463, as amended (5 U.S.C. Appendix 2), which sets forth
standards for the formation and use of advisory committees.
Dated: June 17, 2021.
Rebecca Haffajee,
Acting Assistant Secretary for Planning and Evaluation.
[FR Doc. 2021-13851 Filed 6-28-21; 8:45 am]
BILLING CODE 4150-05-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 29, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.